Jongerius Ilse, Köhl Jörg, Pandey Manoj K, Ruyken Maartje, van Kessel Kok P M, van Strijp Jos A G, Rooijakkers Suzan H M
Medical Microbiology, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands.
J Exp Med. 2007 Oct 1;204(10):2461-71. doi: 10.1084/jem.20070818. Epub 2007 Sep 24.
To combat the human immune response, bacteria should be able to divert the effectiveness of the complement system. We identify four potent complement inhibitors in Staphylococcus aureus that are part of a new immune evasion cluster. Two are homologues of the C3 convertase modulator staphylococcal complement inhibitor (SCIN) and function in a similar way as SCIN. Extracellular fibrinogen-binding protein (Efb) and its homologue extracellular complement-binding protein (Ecb) are identified as potent complement evasion molecules, and their inhibitory mechanism was pinpointed to blocking C3b-containing convertases: the alternative pathway C3 convertase C3bBb and the C5 convertases C4b2aC3b and C3b2Bb. The potency of Efb and Ecb to block C5 convertase activity was demonstrated by their ability to block C5a generation and C5a-mediated neutrophil activation in vitro. Further, Ecb blocks C5a-dependent neutrophil recruitment into the peritoneal cavity in a mouse model of immune complex peritonitis. The strong antiinflammatory properties of these novel S. aureus-derived convertase inhibitors make these compounds interesting drug candidates for complement-mediated diseases.
为了对抗人体免疫反应,细菌应该能够改变补体系统的有效性。我们在金黄色葡萄球菌中鉴定出四种有效的补体抑制剂,它们是一个新的免疫逃避簇的一部分。其中两种是C3转化酶调节剂葡萄球菌补体抑制剂(SCIN)的同源物,其功能与SCIN类似。细胞外纤维蛋白原结合蛋白(Efb)及其同源物细胞外补体结合蛋白(Ecb)被鉴定为有效的补体逃避分子,其抑制机制被确定为阻断含C3b的转化酶:替代途径C3转化酶C3bBb以及C5转化酶C4b2aC3b和C3b2Bb。Efb和Ecb阻断C5转化酶活性的能力通过它们在体外阻断C5a生成和C5a介导的中性粒细胞活化的能力得到证明。此外,在免疫复合物性腹膜炎小鼠模型中,Ecb可阻断C5a依赖性中性粒细胞向腹腔的募集。这些新型金黄色葡萄球菌衍生的转化酶抑制剂具有强大的抗炎特性,使其成为补体介导疾病的有趣候选药物。